Jubilant Therapeutics Inc

Biotechnology ResearchPennsylvania, United States11-50 Employees

Jubilant Therapeutics Inc is a clinical-stage biotechnology company focused on developing small molecule modulators aimed at oncology and autoimmune diseases. Its portfolio includes agents designed to address specific unmet medical needs, with an emphasis on targeted mechanisms that could influence disease pathways. The organization emphasizes a science-driven leadership and independent governance, drawing input from globally recognized experts to guide its clinical program decisions.
Headquartered in Yardley, Pennsylvania, the company operates within the biotechnology research industry and maintains strategic leadership and advisory relationships to advance its drug candidates toward clinical evaluation. Its activities have included appointing experienced executives and board members to oversee development, with ongoing efforts in PAD4 inhibition, dual LSD1/HDAC6 inhibition, and novel brain-penetrant PRMT5 inhibitors, alongside exploratory initiatives in PD-L1–targeting small molecules. A recent leadership appointment in late 2025 reflects continued organizational evolution as it pursues its oncology and autoimmune disease programs.

Sign up for free to view info

Email Format Employee directory